3SBio Gives Selecta Exclusive License To Develop Gout Drug
This article was originally published in PharmAsia News
Executive Summary
China's 3SBio and Selecta Biosciences have reached an agreement giving the U.S. drug maker an exclusive license to develop Uricase PEG-20 (pegsiticase) for treating gout.